This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shao, H. Articles by Tweardy, D. J. Search for Related Content PubMed PubMed Citation Articles by Shao, H. Articles by Tweardy, D. J.

Identification and Characterization of Signal Transducer and Activator of Transcription 3 Recruitment Sites within the Epidermal Growth Factor Receptor¹

Section of Infectious Diseases, Department of Medicine [H. S., D. J. T.], Department of Pathology [H. Y. C.], and Department of Immunology [R. G. C.], Baylor College of Medicine, Houston, Texas 77030

The oncogene signal transducer and activator of transcription 3 (Stat3) is constitutively activated in a wide variety of human cancers, including squamous cell carcinoma of the head and neck. In squamous cell carcinoma of the head and neck, Stat3 activation is mediated by up-regulation of the autocrine ligand-receptor pair, tumor growth factor and epidermal growth factor receptor (EGFR), resulting in cell growth and resistance to apoptosis. The initiating molecular event in Stat3 activation is recruitment to specific phosphotyrosine motifs within signaling complexes. Stat3 activation by the EGFR has been mapped to the COOH-terminal region of the EGFR between amino acid residues 1061 and 1123, which contains Y1068 and Y1086. However, it is not known if Stat3 binds directly to the EGFR or if either of these tyrosines is involved in this interaction. In this study, we demonstrated in stably transfected NIH-3T3 cells that activation of Stat3 by EGFR was eliminated by mutation of all five EGFR tyrosines to phenylalanine and that activation was restored with return of two of the mutated tyrosine sites, Y1068 and Y1086, to wild-type. Stat3 was detected in the activated EGFR complex, and its presence within the complex was dependent on Y1068 and/or Y1086. Phosphododecapeptides spanning Y1068 and Y1086 were able to pull down Stat3 with Y1068 being more effective than Y1086 in this regard. Real-time mirror resonance affinity analysis revealed Stat3 bound to phosphododecapeptide Y1068 with a K_D of 135 ± 20 nM and to phosphododecapeptide Y1086 with a K_D of 243 ± 36 nM (P = 0.044), consistent with the results of the pull-down assays. The lower K_D of Y1068 was completely attributable to slower dissociation of Stat3 bound to Y1068 versus Y1086. Each phosphododecapeptide was capable of destabilizing Stat3 homodimers in vitro. When delivered into squamous carcinoma cells, phosphopeptides spanning Y1068 and Y1086 were able to inhibit EGFR-stimulated Stat3 DNA binding activity and cell proliferation.

This article has been cited by other articles:

				P. H. Huang, A. M. Xu, and F. M. White Oncogenic EGFR Signaling Networks in Glioma Sci. Signal., September 8, 2009; 2(87): re6 - re6. [Abstract] [Full Text] [PDF]

				C. Li, Y. Zang, M. Sen, R. J. Leeman-Neill, D. SK. Man, J. R. Grandis, and D. E. Johnson Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death Mol. Cancer Ther., August 1, 2009; 8(8): 2211 - 2220. [Abstract] [Full Text] [PDF]

				N. V. Broadbelt, J. Chen, R. B. Silver, D. P. Poppas, and D. Felsen Pressure activates epidermal growth factor receptor leading to the induction of iNOS via NF{kappa}B and STAT3 in human proximal tubule cells Am J Physiol Renal Physiol, July 1, 2009; 297(1): F114 - F124. [Abstract] [Full Text] [PDF]

				A. L. Boehm, M. Sen, R. Seethala, W. E. Gooding, M. Freilino, S. M. Y. Wong, S. Wang, D. E. Johnson, and J. R. Grandis Combined Targeting of Epidermal Growth Factor Receptor, Signal Transducer and Activator of Transcription-3, and Bcl-XL Enhances Antitumor Effects in Squamous Cell Carcinoma of the Head and Neck Mol. Pharmacol., June 1, 2008; 73(6): 1632 - 1642. [Abstract] [Full Text] [PDF]

				R. R. Seethala, W. E. Gooding, P. N. Handler, B. Collins, Q. Zhang, J. M. Siegfried, and J. R. Grandis Immunohistochemical Analysis of Phosphotyrosine Signal Transducer and Activator of Transcription 3 and Epidermal Growth Factor Receptor Autocrine Signaling Pathways in Head and Neck Cancers and Metastatic Lymph Nodes Clin. Cancer Res., March 1, 2008; 14(5): 1303 - 1309. [Abstract] [Full Text] [PDF]

				Y. Nieto, F. Nawaz, R. B. Jones, E. J. Shpall, and S. Nawaz Prognostic Significance of Overexpression and Phosphorylation of Epidermal Growth Factor Receptor (EGFR) and the Presence of Truncated EGFRvIII in Locoregionally Advanced Breast Cancer J. Clin. Oncol., October 1, 2007; 25(28): 4405 - 4413. [Abstract] [Full Text] [PDF]

				H. Shao, X. Xu, N. Jing, and D. J. Tweardy Unique structural determinants for stat3 recruitment and activation by the granulocyte colony-stimulating factor receptor at phosphotyrosine ligands 704 and 744. J. Immunol., March 1, 2006; 176(5): 2933 - 2941. [Abstract] [Full Text] [PDF]

				H. Siavash, N.G. Nikitakis, and J.J. Sauk SIGNAL TRANSDUCERS AND ACTIVATORS OF TRANSCRIPTION: INSIGHTS INTO THE MOLECULAR BASIS OF ORAL CANCER Critical Reviews in Oral Biology & Medicine, September 1, 2004; 15(5): 298 - 307. [Abstract] [Full Text] [PDF]

				H. Shao, X. Xu, M.-A. A. Mastrangelo, N. Jing, R. G. Cook, G. B. Legge, and D. J. Tweardy Structural Requirements for Signal Transducer and Activator of Transcription 3 Binding to Phosphotyrosine Ligands Containing the YXXQ Motif J. Biol. Chem., April 30, 2004; 279(18): 18967 - 18973. [Abstract] [Full Text] [PDF]